In a 36‑year‑old man with intermittent constipation and persistent epigastric dyspepsia after a full‑dose proton‑pump inhibitor (omeprazole 20 mg twice daily) for two months, what are the appropriate next diagnostic and therapeutic steps?

PPI Failed After 2 Months: Next Steps

In a 36-year-old man with persistent epigastric dyspepsia after 2 months of full-dose PPI (omeprazole 20 mg twice daily), the next step is to perform upper endoscopy (EGD) with biopsies for H. pylori testing, as this represents treatment-refractory dyspepsia requiring diagnostic evaluation before escalating therapy 1.

Diagnostic Approach

Immediate Actions

• Perform EGD with gastric biopsies for H. pylori testing 1

  • While this patient is under 55 years without alarm symptoms, the 2022 British Society of Gastroenterology guidelines specifically recommend non-urgent endoscopy for patients ≥55 years with treatment-resistant dyspepsia 1
  • The 2005 AGA guidelines support endoscopy after failed empirical therapy (Figure 3) 2
  • At age 36, endoscopy is reasonable given 2 months of failed full-dose PPI therapy

• Test for H. pylori if not already done 1

  • If positive: eradicate with appropriate triple or quadruple therapy
  • If negative or already eradicated: proceed with alternative management

Important Caveat About Gastric Malignancy

The FDA label for omeprazole explicitly warns: "symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy" and recommends additional follow-up and diagnostic testing in patients with suboptimal response 3. While gastric cancer is uncommon at age 36, endoscopy rules out this possibility definitively.

Therapeutic Algorithm After Endoscopy

If H. pylori Positive

1. Complete eradication therapy
2. Confirm eradication in this patient (given treatment failure pattern) 1
3. Resume PPI trial for 4-6 weeks post-eradication 2

If H. pylori Negative or Already Eradicated

Second-line treatment options (in order of evidence strength):

1. Tricyclic antidepressants (TCAs) - STRONGEST recommendation

   • Start amitriptyline 10 mg once daily at bedtime
   • Titrate slowly to 30-50 mg once daily as tolerated
   • This has strong recommendation with moderate quality evidence as second-line therapy 1
   • Counsel patient this is used as a "gut-brain neuromodulator" for visceral hypersensitivity, not for depression
   • More effective than continuing or escalating PPI therapy

2. Prokinetic agents (if available)

   • Consider for postprandial distress syndrome subtype
   • Options include itopride, acotiamide, or mosapride (availability varies by region)
   • Weak to moderate evidence 1

3. H2-receptor antagonists as alternative acid suppression

   • May be tried if not already attempted
   • Weak evidence but well-tolerated 1

What NOT to Do

• Do not simply increase PPI dose or switch to another PPI - The 2022 BSG guidelines state "there does not appear to be a dose response" for PPIs in functional dyspepsia 1. Your patient is already on twice-daily dosing (omeprazole 20 mg BID = 40 mg total daily), which is adequate.

• Do not routinely order gastric emptying studies or 24-hour pH monitoring - Strong recommendation against this in typical FD 1

• Do not order abdominal ultrasound or celiac serology unless IBS-type symptoms are prominent 1, 4

Addressing the Constipation

The intermittent constipation mentioned may represent:

• Overlap with IBS (consider Rome IV criteria)
• Side effect of any anticholinergic medications
• Separate functional bowel disorder

If IBS overlap is present, this doesn't change the dyspepsia management algorithm but may influence choice of neuromodulator (TCAs can worsen constipation; consider mirtazapine as alternative) 1, 4.

Referral Considerations

Refer to gastroenterology if 1:

• Diagnostic doubt persists after endoscopy
• Symptoms remain severe or refractory to TCA trial
• Patient requests specialist opinion
• Access to multidisciplinary care including dietary support and gut-brain behavioral therapies is needed

The evidence strongly supports moving beyond simple PPI manipulation in this scenario. The combination of endoscopy for definitive diagnosis plus initiation of neuromodulator therapy represents the evidence-based pathway forward 1.